This move is archived. Current quotes and coverage live on the stock page.
Get BCT alerts:
Briacell Therapeutics Corp is seeing a significant rise in its stock price, reflecting investor optimism.
In the last trading session, Briacell Therapeutics Corp (BCT.TO) saw its stock price increase by 2.82%, closing at CA$4.01. This uptick comes amid ongoing developments in the biotech sector, especially regarding cancer therapies.
Investor takeaway: Investors are responding positively to Briacell's advancements in immunotherapy, which could position the company favorably in the competitive biotech landscape.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$43.93M
52W high
$20.40
52W low
$3.68
1W change
+2.46%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 300.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+300.8% Upside
Current Price
C$4.99
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
81.5%
Annualized
90-Day Vol
87.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.97
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.30 | C$4.00 โ C$7.02 |
| 60 trading days | C$5.62 | C$3.78 โ C$8.37 |
| 90 trading days | C$5.97 | C$3.67 โ C$9.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Briacell's Market Cap Surpasses CA$34 Million
With a market cap of CA$34,886,148, Briacell is gaining traction among investors, reflecting confidence in its innovative therapies.
Bull case
The recent rise in stock price likely stems from Briacell's promising clinical trial results and FDA clearances. These achievements boost the company's credibility and enhance its potential for future growth.
Bear case
Despite the positive movement, investors should remain cautious. The biotech sector is known for its volatility, and ongoing trials may produce mixed results.
Advertisement
Recent Performance Overview
Briacell's stock performance in the last trading session shows positive sentiment among investors, with shares climbing 2.82%. This increase is noteworthy given the company's focus on developing immunotherapies for cancer, which are gaining traction in the medical community.
Market Sentiment and Future Prospects
The rise in Briacell's share price is linked to recent advancements in its clinical trials and the potential for FDA approvals. Investors are optimistic that these developments will lead to greater market opportunities and revenue growth, positioning Briacell as a key player in the biotech industry.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
